Research programme: fusion proteins - MicrometAlternative Names: Fusion proteins research programme - Micromet
Latest Information Update: 06 Sep 2002
At a glance
- Originator Micromet; Nonindustrial source
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 27 Oct 1998 Preclinical development for Cancer in Germany (Unknown route)